The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...

"Time has stood still" for many who've been on complex regimens for decades ...

Post-exposure prophylaxis-in-pocket (PIP) was associated with healthcare savings and improved quality of life outcomes compared to pre-exposure prophylaxis (PrEP), based on data presented at ...

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in ...

At 48 weeks, 1% of participants in both groups had an HIV-1 RNA level of 50 copies per milliliter or higher, meeting the ...

Injectable cabotegravir + rilpivirine reduced regimen failure risk compared with daily oral therapy in patients with HIV and adherence challenges.

Development assistance for health has fallen back toward 2010 levels, disproportionately disrupting community-based HIV services and projecting increased infections and AIDS-related deaths.

GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.

VH184, the first, third-generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency ...

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...